MedTrace Logo

Effect on RLS Symptom Severity After Switching to Neupro® in Patients Who Previously Experienced Augmentation

NCT01386944 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2018-04-04

Study results available
· View outcomes & findings →

Summary

The objective is to assess the effect of Neupro® on the severity of Restless Leg Syndrome (RLS) symptoms and augmentation in patients with augmentation associated with previous oral dopaminergic therapy. In addition, the change in treatment regimen used when switching to Neupro® will be evaluated.

Conditions

  • Restless Legs Syndrome

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01386944 on ClinicalTrials.gov